

# ROCK<sup>®</sup> Platform

## Actualizing the Untapped Potential of the Innate Immune System Pioneering immune cell engagers

### Affimed N.V.

Affimed (Nasdaq: AFMD) engineers targeted immunotherapies, seeking to improve patient outcomes through giving back the patients innate ability to fight cancer. Our fit-for-purpose ROCK<sup>®</sup> platform allows innate immune engagers to be designed for specific patient populations. We are developing single and combination therapies to treat cancers.

### Affimed's ROCK<sup>®</sup> Platform - Redirected Optimized Cell Killing

Affimed's unique ROCK<sup>®</sup> platform enables the generation of first-in-class tetravalent, multi-specific immune cell engagers. This proprietary platform supports innate and adaptive drug development (NK cell and macrophage engagers, and T cell engagers) and, based on its modularity, allows for antibody engineering of highly customizable immune cell engagers tailored to different indications and settings. A prerequisite for redirected optimized cell killing enabling the development of effective therapies is the ability to utilize different antibody formats and immune effector cell types. Affimed's ROCK<sup>®</sup> platform addresses this need.

#### Affimed's ROCK<sup>®</sup> Platform

- Suitable for the development of both innate and adaptive immune cell engagers, thus employing both innate and adaptive immunity to fight cancer
- Generates antibody candidates tailored to different indications and settings
- Supports the potential for tetravalent and multi-specific formats
- Allows for the generation of engagers with variable pharmacokinetic (PK) profiles
- Enables the generation of immune cell engagers with favorable manufacturing properties

ROCK<sup>®</sup>'s modularity is built on a toolbox of proprietary formats and long-standing engineering know-how: A combination of competencies essential for the construction of novel, potent and custom immune cell engagers.

#### Partnerships with Industry, Academia and Advocacy Groups

##### Genentech

Collaboration to develop novel NK cell engager-based immunotherapeutics

- **\$96M** Upfront payment
- **\$5B** Potential milestones, royalties

##### AbCheck

##### Amphivena Therapeutics Inc.

##### German Hodgkin Study Group

##### Leukemia and Lymphoma Society

##### MD Anderson Cancer Center

##### Merck & Co., Inc.

## Redirected Optimized Cell Killing (ROCK®)


Redirecting innate and adaptive immune cells with multi-specific antibodies to achieve optimized killing of malignant cells is a powerful novel approach for therapy of cancer patients.

## Affimed's Long-Standing Expertise

Affimed has long-standing expertise in drug development of differentiated immune cell engagers and protein engineering, enabling the design of a novel class of tetravalent, multi-specific formats.

### ROCK® Platform

A versatile platform of immune cell engagers based on a proprietary toolbox and modularity



## Affimed Highlights

- ✓ Lead product candidate: AFM13 most advanced innate cell engager in clinical development
  - Positive efficacy data as monotherapy in HL and in CD30-positive lymphoma
  - Encouraging efficacy in combination with Keytruda®: Best response data: ORR of 88% and CR rate of 42%/46% (local/central read)
  - Suitable for combinations with checkpoint inhibitors, adoptive NK cell transfer or cytokines
- ✓ Diverse pipeline of clinical and preclinical assets based on tetravalent bispecific antibody formats

## Management Team

Proven track record in biotech, pharma, product development and finance

### Adi Hoess, PhD, CEO

- CEO since 2011
- Led AFMD IPO in 2014
- MorphoSys, Jerini

### Florian Fischer, PhD, CFO

- CFO since 2005
- Led AFMD IPO in 2014
- Deutsche Bank and KPMG

### Wolfgang Fischer, PhD, COO

- Joined 2017 from Sandoz (Novartis)
- Global Head Program&Project Mgmt
- Regional Medical Director Hematology

### Leila Alland, MD, CMO

- Joined 2018 from Tarveda Therapeutics
- Oncology lead at AZ, BMS and Novartis

### Martin Treder, PhD, CSO

- Joined 2015 from CT Atlantic (Swiss I/O)
- Co-founder U3 Pharma (targeted cancer therapeutics)

### Denise Mueller, CBO

- Joined 2016 from Pfizer
- US & global marketing, Pfizer and Wyeth

Affimed

Technologiepark  
Im Neuenheimer Feld 582  
69120 Heidelberg, Germany

Contact Us

info@affimed.com  
www.affimed.com

